Collapsible content

ANXIETY

  1. Cannabidiol modulates serotonergic transmission and reverses both allodynia and anxiety-like behavior in a model of neuropathic pain
  2. Cannabidiol treatment in an adolescent with multiple substance abuse, social anxiety and depression
  3. Cannabidiolic acid methyl ester, a stable synthetic analogue of cannabidiolic acid, can produce 5-HT1A receptor-mediated suppression of nausea and anxiety in rats
  4. Cannabidiol regulation of emotion and emotional memory processing: relevance for treating anxiety-related and substance abuse disorders
  5. Cannabidiol Does Not Dampen Responses to Emotional Stimuli in Healthy Adults
  6. Effect of prior foot shock stress and Δ9-tetrahydrocannabinol, cannabidiolic acid, and cannabidiol on anxiety-like responding in the light-dark emergence test in rats
  7. Inverted U-Shaped Dose-Response Curve of the Anxiolytic Effect of Cannabidiol during Public Speaking in Real Life
  8. Cannabidiol regulation of emotion and emotional memory processing: relevance for treating anxiety-related and substance abuse disorders
  9. Effectiveness of Cannabidiol Oil for Pediatric Anxiety and Insomnia as Part of Posttraumatic Stress Disorder: A Case Report
  10. Cannabidiol is a negative allosteric modulator of the cannabinoid CB1 receptor
  11. Antidepressant-like and anxiolytic-like effects of cannabidiol: a chemical compound of Cannabis sativa
  12. The anxiolytic effect of cannabidiol on chronically stressed mice depends on hippocampal neurogenesis: involvement of the endocannabinoid system
  13. Does Cannabidiol Protect Against Adverse Psychological Effects of THC?
  14. Cannabidiol, a Cannabis sativa constituent, as an anxiolytic drug
  15. The anxiolytic effect of cannabidiol on chronically stressed mice depends on hippocampal neurogenesis: involvement of the endocannabinoid system
  16. Cannabidiol reduces the anxiety induced by simulated public speaking in treatment-naïve social phobia patients
  17. Neural basis of anxiolytic effects of cannabidiol (CBD) in generalized social anxiety disorder: a preliminary report
  18. Cannabidiol reduces the anxiety induced by simulated public speaking in treatment-naïve social phobia patients
  19. Neural basis of anxiolytic effects of cannabidiol (CBD) in generalized social anxiety disorder: a preliminary report
  20. Distinct effects of {delta}9-tetrahydrocannabinol and cannabidiol on neural activation during emotional processing
  21. Effects of cannabidiol (CBD) on regional cerebral blood flow
  22. Endocannabinoids, cannabinoids and the regulation of anxiety
  23. Cannabidiol as a Potential Treatment for Anxiety Disorders

CANCER

  1. Striking lung cancer response to self-administration of cannabidiol: A case report and literature review
  2. Cannabidiol-induced apoptosis is mediated by activation of Noxa in human colorectal cancer cells
  3. Concomitant Treatment of Malignant Brain Tumours With CBD - A Case Series and Review of the Literature
  4. Report of Objective Clinical Responses of Cancer Patients to Pharmaceutical-grade Synthetic Cannabidiol
  5. Cannabidiol rather than Cannabis sativa extracts inhibit cell growth and induce apoptosis in cervical cancer cells
  6. Inhibition of colon carcinogenesis by a standardized Cannabis sativa extract with high content of cannabidiol
  7. Cannabidiol as potential anticancer drug
  8. Cannabidiol, a non-psychoactive cannabinoid compound, inhibits proliferation and invasion in U87-MG and T98G glioma cells through a multitarget effect
  9. Triggering of the TRPV2 channel by cannabidiol sensitizes glioblastoma cells to cytotoxic chemotherapeutic agents
  10. An open-label extension study to investigate the long-term safety and tolerability of THC/CBD oromucosal spray and oromucosal THC spray in patients with terminal cancer-related pain refractory to strong opioid analgesics
  11. Non-THC cannabinoids inhibit prostate carcinoma growth in vitro and in vivo: pro-apoptotic effects and underlying mechanisms
  12. COX-2 and PPAR-γ confer cannabidiol-induced apoptosis of human lung cancer cells
  13. Cannabidiol as potential anticancer drug
  14. Cannabidiol inhibits growth and induces programmed cell death in kaposi sarcoma-associated herpesvirus-infected endothelium
  15. Cannabidiol inhibits lung cancer cell invasion and metastasis via intercellular adhesion molecule-1
  16. Cannabidiol inhibits growth and induces programmed cell death in kaposi sarcoma-associated herpesvirus-infected endothelium
  17. Chemopreventive effect of the non-psychotropic phytocannabinoid cannabidiol on experimental colon cancer
  18. Cannabidiol induces programmed cell death in breast cancer cells by coordinating the cross-talk between apoptosis and autophagy
  19. Pathways mediating the effects of cannabidiol on the reduction of breast cancer cell proliferation, invasion, and metastasis
  20. Cannabidiol induces programmed cell death in breast cancer cells by coordinating the cross-talk between apoptosis and autophagy
  21. Multicenter, double-blind, randomized, placebo-controlled, parallel-group study of the efficacy, safety, and tolerability of THC:CBD extract and THC extract in patients with intractable cancer-related pain
  22. Cannabidiol enhances the inhibitory effects of delta9-tetrahydrocannabinol on human glioblastoma cell proliferation and survival
  23. A comparative study on cannabidiol-induced apoptosis in murine thymocytes and EL-4 thymoma cells
  24. Cannabidiol as a novel inhibitor of Id-1 gene expression in aggressive breast cancer cells
  25. Antitumor activity of plant cannabinoids with emphasis on the effect of cannabidiol on human breast carcinoma
  26. Cannabidiol-induced apoptosis in human leukemia cells: A novel role of cannabidiol in the regulation of p22phox and Nox4 expression
  27. Gamma-irradiation enhances apoptosis induced by cannabidiol, a non-psychotropic cannabinoid, in cultured HL-60 myeloblastic leukemia cells
  28. Cannabidiol Effectively Promoted Cell Death in Bladder Cancer and the Improved Intravesical Adhesion Drugs Delivery Strategy Could Be Better Used for Treatment
  29. 29. The Pathophysiology and the Therapeutic Potential of Cannabinoids in Prostate Cancer
  30. 30. Cannabidiol directly targets mitochondria and disturbs calcium homeostasis in acute lymphoblastic leukemia
  31. Cannabinoids as therapeutic agents in cancer: current status and future implications
  32. Cannabinoids Induce Cancer Cell Proliferation via Tumor Necrosis Factor α-Converting Enzyme (TACE/ADAM17)-Mediated Transactivation of the Epidermal Growth Factor Receptor
  33. Cannabinoids for Cancer Treatment: Progress and Promise

EPILEPSY

  1. Cannabidiol (CBD) and cognition in epilepsy
  2. Cross-sectional and longitudinal evaluation of cannabidiol (CBD) product use and health among people with epilepsy
  3. UHPLC-MS/MS Analysis of Cannabidiol and Its Metabolites in Serum of Patients with Resistant Epilepsy Treated with CBD Formulations
  4. The results of this multicenter study on CBD treatment for intractable epilepsy in a population of children and adolescents are highly promising. Further prospective, well-designed clinical trials using enriched CBD medical cannabis are warranted.
  5. Anticonvulsive Properties of Cannabidiol in a Model of Generalized Seizure Are Transient Receptor Potential Vanilloid 1 Dependent
  6. Epilepsy and cannabidiol: a guide to treatment
  7. Cannabidiol in treatment of refractory epileptic spasms: An open-label study
  8. The proposed mechanisms of action of CBD in epilepsy
  9. Dose-Ranging Effect of Adjunctive Oral Cannabidiol vs Placebo on Convulsive Seizure Frequency in Dravet Syndrome: A Randomized Clinical Trial
  10. Cost-effectiveness of cannabinoids for pediatric drug-resistant epilepsy: protocol for a systematic review of economic evaluations
  11. Update on Antiepileptic Drugs 2019
  12. Randomized blinded controlled clinical trial to assess the effect of oral cannabidiol administration in addition to conventional antiepileptic treatment on seizure frequency in dogs with intractable idiopathic epilepsy
  13. Food effect on pharmacokinetics of cannabidiol oral capsules in adult patients with refractory epilepsy
  14. Cannabis-based products for pediatric epilepsy: A systematic review
  15. Long-term cannabidiol treatment in patients with Dravet syndrome: An open-label extension trial
  16. Cannabidiol in patients with Lennox-Gastaut syndrome: Interim analysis of an open-label extension study
  17. Drug-drug interactions with cannabidiol (CBD) appear to have no effect on treatment response in an open-label Expanded Access Program
  18. Long-Term Safety, Tolerability, and Efficacy of Cannabidiol in Children with Refractory Epilepsy: Results from an Expanded Access Program in the US
  19. Pharmacological and Therapeutic Properties of Cannabidiol for Epilepsy
  20. Quality of life in adults enrolled in an open-label study of cannabidiol (CBD) for treatment-resistant epilepsy
  21. Potential Clinical Benefits of CBD-Rich Cannabis Extracts Over Purified CBD in Treatment-Resistant Epilepsy: Observational Data Meta-analysis
  22. Cannabidiol in patients with seizures associated with Lennox-Gastaut syndrome (GWPCARE4): a randomised, double-blind, placebo-controlled phase 3 trial
  23. Cannabidiol for Treatment of Childhood Epilepsy-A Cross-Sectional Survey
  24. Effect of Cannabidiol on Drop Seizures in the Lennox-Gastaut Syndrome
  25. Interactions between cannabidiol and commonly used antiepileptic drugs
  26. Cannabidiol attenuates seizures and social deficits in a mouse model of Dravet syndrome
  27. Historical perspective on the medical use of cannabis for epilepsy: Ancient times to the 1980s
  28. CBD-enriched medical cannabis for intractable pediatric epilepsy: The current Israeli experience
  29. Cannabidiol in patients with treatment-resistant epilepsy: an open-label interventional trial
  30. Cannabinoids and Epilepsy
  31. Cannabidiol: pharmacology and potential therapeutic role in epilepsy and other neuropsychiatric disorders
  32. Nonpsychotropic plant cannabinoids, cannabidivarin (CBDV) and cannabidiol (CBD), activate and desensitize transient receptor potential vanilloid 1 (TRPV1) channels in vitro: potential for the treatment of neuronal hyperexcitability
  33. Drug-drug interaction between clobazam and cannabidiol in children with refractory epilepsy
  34. Cannabidiol displays antiepileptiform and antiseizure properties in vitro and in vivo
  35. Downregulation of the CB1 cannabinoid receptor and related molecular elements of the endocannabinoid system in epileptic human hippocampus

MULTIPLE SCLEROSIS

  1. Cannabidiol provides long-lasting protection against the deleterious effects of inflammation in a viral model of multiple sclerosis: a role for A2A receptors
  2. A double-blind, randomized, placebo-controlled, parallel-group study of THC/CBD oromucosal spray in combination with the existing treatment regimen, in the relief of central neuropathic pain in patients with multiple sclerosis
  3. Nabiximols (THC/CBD oromucosal spray, Sativex®) in clinical practice--results of a multicenter, non-interventional study (MOVE 2) in patients with multiple sclerosis spasticity
  4. Cannabidiol Attenuates Experimental Autoimmune Encephalomyelitis Model of Multiple Sclerosis Through Induction of Myeloid-Derived Suppressor Cells
  5. Daily Practice Managing Resistant Multiple Sclerosis Spasticity With Delta-9-Tetrahydrocannabinol: Cannabidiol Oromucosal Spray: A Systematic Review of Observational Studies
  6. Cannabidiol provides long-lasting protection against the deleterious effects of inflammation in a viral model of multiple sclerosis: a role for A2A receptors
  7. Symptomatic therapy in multiple sclerosis: the role of cannabinoids in treating spasticity
  8. A placebo-controlled, parallel-group, randomized withdrawal study of subjects with symptoms of spasticity due to multiple sclerosis who are receiving long-term Sativex® (nabiximols)
  9. Cannabidiol inhibits pathogenic T cells, decreases spinal microglial activation and ameliorates multiple sclerosis-like disease in C57BL/6 mice
  10. Meta-analysis of the efficacy and safety of Sativex (nabiximols), on spasticity in people with multiple sclerosis
  11. Cannabinoids in the management of spasticity associated with multiple sclerosis
  12. Oromucosal delta9-tetrahydrocannabinol/cannabidiol for neuropathic pain associated with multiple sclerosis: an uncontrolled, open-label, 2-year extension trial
  13. Meta-analysis of cannabis based treatments for neuropathic and multiple sclerosis-related pain
  14. Cannabinoid control of neuroinflammation related to multiple sclerosis
  15. Sativex: clinical efficacy and tolerability in the treatment of symptoms of multiple sclerosis and neuropathic pain
  16. An open-label pilot study of cannabis-based extracts for bladder dysfunction in advanced multiple sclerosis
  17. The cannabinoids: an overview. Therapeutic implications in vomiting and nausea after cancer chemotherapy, in appetite promotion, in multiple sclerosis and in neuroprotection

PAIN

  1. Effects of cannabis ingestion on endometriosis-associated pelvic pain and related symptoms
  2. Cannabinoid Formulations and Delivery Systems: Current and Future Options to Treat Pain
  3. Prevalence of Cannabidiol Use in Patients With Spine Complaints: Results of an Anonymous Survey
  4. Cannabinoids and Pain: New Insights From Old Molecules
  5. Cannabidiol modulates serotonergic transmission and reverses both allodynia and anxiety-like behavior in a model of neuropathic pain
  6. Effects of cannabidiol in males and females in two different rat models of depression
  7. Cannabidiol in Anxiety and Sleep: A Large Case Series
  8. Cannabidiol as adjunctive treatment of seizures associated with Lennox-Gastaut syndrome and Dravet syndrome
  9. Cannabidiol for Pain Treatment: Focus on Pharmacology and Mechanism of Action
  10. Evaluation of the effects of CBD hemp extract on opioid use and quality of life indicators in chronic pain patients: a prospective cohort study
  11. Medicinal Properties of Cannabinoids, Terpenes, and Flavonoids in Cannabis, and Benefits in Migraine, Headache, and Pain: An Update on Current Evidence and Cannabis Science
  12. Medical Cannabis for Neuropathic Pain
  13. Chronic Pain Treatment With Cannabidiol in Kidney Transplant Patients in Uruguay
  14. Patterns of medicinal cannabis use, strain analysis, and substitution effect among patients with migraine, headache, arthritis, and chronic pain in a medicinal cannabis cohort
  15. Attenuation of early phase inflammation by cannabidiol prevents pain and nerve damage in rat osteoarthritis
  16. Single and combined effects of Δ9 -tetrahydrocannabinol and cannabidiol in a mouse model of chemotherapy-induced neuropathic pain
  17. Neurophysiologic Correlates of Headache Pain in Subjects With Major Depressive Disorder
  18. Cannabidiol-Δ9-tetrahydrocannabinol interactions on acute pain and locomotor activity
  19. Cannabidiol Is a Potential Therapeutic for the Affective-Motivational Dimension of Incision Pain in Rats
  20. Low-Dose Cannabidiol Is Safe but Not Effective in the Treatment for Crohn's Disease, a Randomized Controlled Trial
  21. Cannabidiol-Δ9-tetrahydrocannabinol interactions on acute pain and locomotor activity
  22. Transdermal cannabidiol reduces inflammation and pain-related behaviours in a rat model of arthritis
  23. A double-blind, randomized, placebo-controlled, parallel group study of THC/CBD spray in peripheral neuropathic pain treatment
  24. A double-blind, randomized, placebo-controlled, parallel-group study of THC/CBD oromucosal spray in combination with the existing treatment regimen, in the relief of central neuropathic pain in patients with multiple sclerosis
  25. An open-label extension study to investigate the long-term safety and tolerability of THC/CBD oromucosal spray and oromucosal THC spray in patients with terminal cancer-related pain refractory to strong opioid analgesics
  26. Multicenter, double-blind, randomized, placebo-controlled, parallel-group study of the efficacy, safety, and tolerability of THC:CBD extract and THC extract in patients with intractable cancer-related pain
  27. Antinociceptive effect of the cannabinoid agonist, WIN 55,212-2, in the orofacial and temporomandibular formalin tests
  28. Sativex successfully treats neuropathic pain characterised by allodynia: a randomised, double-blind, placebo-controlled clinical trial
  29. Cannabis, pain, and sleep: lessons from therapeutic clinical trials of Sativex, a cannabis-based medicine
  30. Oromucosal delta9-tetrahydrocannabinol/cannabidiol for neuropathic pain associated with multiple sclerosis: an uncontrolled, open-label, 2-year extension trial
  31. The non-psychoactive cannabis constituent cannabidiol is an orally effective therapeutic agent in rat chronic inflammatory and neuropathic pain
  32. Cannabidiol is an allosteric modulator at mu- and delta-opioid receptors
  33. Vanilloid TRPV1 receptor mediates the antihyperalgesic effect of the nonpsychoactive cannabinoid, cannabidiol, in a rat model of acute inflammation
  34. Cannabidiol-transdermal delivery and anti-inflammatory effect in a murine model
  35. The cannabinoids: an overview. Therapeutic implications in vomiting and nausea after cancer chemotherapy, in appetite promotion, in multiple sclerosis and in neuroprotection

  • Disclaimer: The information provided on this page is intended for general informational purposes only and should not be considered as medical advice, diagnosis, or treatment.